Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder
JAMA Oncology April 13, 2023 Manish Agrawal, Ezekiel Emanuel, Brian D. Richards et al. 48 citations
In a nonrandomized controlled trial, psilocybin was administered to groups of patients with cancer who also had major depressive disorder, using a one-to-one therapist-to-patient ratio. The aim was to develop a scalable, rapidly effective depression treatment. The trial suggests that this approach may offer a feasible model for delivering psilocybin therapy to larger numbers of patients while maintaining therapeutic support.